Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:IMCR NASDAQ:JANX NYSEAMERICAN:LCTX OTCMKTS:TRUU On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIMCRImmunocore$34.39+8.4%$33.67$23.15▼$39.33$1.73B0.79332,959 shs369,852 shsJANXJanux Therapeutics$28.28+9.9%$23.90$21.73▼$71.71$1.70B2.82914,295 shs1.84 million shsLCTXLineage Cell Therapeutics$1.81+1.1%$1.37$0.37▼$1.85$413.33M1.771.86 million shs1.35 million shsTRUUTrue Drinks$0.29-8.1%$0.27$0.00▼$0.08$1.42B10.91.01 million shs248,885 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIMCRImmunocore-1.95%-7.31%-9.99%-11.25%-1.46%JANXJanux Therapeutics-2.13%+13.40%+6.99%-4.70%-47.86%LCTXLineage Cell Therapeutics+1.13%+3.47%+33.58%+75.49%+108.38%TRUUTrue Drinks-3.43%-3.43%+1.97%+228.04%+261.73%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIMCRImmunocore$34.39+8.4%$33.67$23.15▼$39.33$1.73B0.79332,959 shs369,852 shsJANXJanux Therapeutics$28.28+9.9%$23.90$21.73▼$71.71$1.70B2.82914,295 shs1.84 million shsLCTXLineage Cell Therapeutics$1.81+1.1%$1.37$0.37▼$1.85$413.33M1.771.86 million shs1.35 million shsTRUUTrue Drinks$0.29-8.1%$0.27$0.00▼$0.08$1.42B10.91.01 million shs248,885 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIMCRImmunocore-1.95%-7.31%-9.99%-11.25%-1.46%JANXJanux Therapeutics-2.13%+13.40%+6.99%-4.70%-47.86%LCTXLineage Cell Therapeutics+1.13%+3.47%+33.58%+75.49%+108.38%TRUUTrue Drinks-3.43%-3.43%+1.97%+228.04%+261.73%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIMCRImmunocore 2.33Hold$56.8965.42% UpsideJANXJanux Therapeutics 2.94Moderate Buy$78.31176.90% UpsideLCTXLineage Cell Therapeutics 3.00Buy$4.25134.81% UpsideTRUUTrue Drinks 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest LCTX, IMCR, JANX, and TRUU Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/8/2025IMCRImmunocoreWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025JANXJanux TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025IMCRImmunocoreWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025JANXJanux TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/18/2025IMCRImmunocoreGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageNeutral9/17/2025JANXJanux TherapeuticsBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$47.009/16/2025JANXJanux TherapeuticsBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$47.009/10/2025JANXJanux TherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$100.009/10/2025JANXJanux TherapeuticsStifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$45.009/4/2025IMCRImmunocoreZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold9/3/2025JANXJanux TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$72.00(Data available from 10/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIMCRImmunocore$310.20M5.59N/AN/A$7.20 per share4.78JANXJanux Therapeutics$439K3,871.20N/AN/A$19.49 per share1.45LCTXLineage Cell Therapeutics$9.50M43.51N/AN/A$0.35 per share5.17TRUUTrue Drinks$1.95M726.78N/AN/A($0.03) per share-9.50Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIMCRImmunocore-$51.09M-$0.40N/AN/AN/A-5.70%-5.40%-1.93%11/5/2025 (Estimated)JANXJanux Therapeutics-$68.99M-$1.80N/AN/AN/AN/A-11.48%-11.01%11/5/2025 (Estimated)LCTXLineage Cell Therapeutics-$18.61M-$0.12N/AN/AN/A-374.84%-20.00%-12.93%11/13/2025 (Estimated)TRUUTrue Drinks-$3.88M$0.0128.50∞N/A-255.80%N/A-165.86%N/ALatest LCTX, IMCR, JANX, and TRUU EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/5/2025Q3 2025IMCRImmunocore-$0.30N/AN/AN/A$137.29 millionN/A11/5/2025Q3 2025JANXJanux Therapeutics-$0.60N/AN/AN/A$3.07 millionN/A8/7/2025Q2 2025IMCRImmunocore-$0.21-$0.20+$0.01-$0.20$122.96 million$130.65 million8/7/2025Q2 2025JANXJanux Therapeutics-$0.48-$0.55-$0.07-$0.55$0.30 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthIMCRImmunocoreN/AN/AN/AN/AN/AJANXJanux TherapeuticsN/AN/AN/AN/AN/ALCTXLineage Cell TherapeuticsN/AN/AN/AN/AN/ATRUUTrue DrinksN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIMCRImmunocore1.015.895.86JANXJanux TherapeuticsN/A47.0347.03LCTXLineage Cell TherapeuticsN/A4.084.08TRUUTrue DrinksN/A0.01N/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIMCRImmunocore84.50%JANXJanux Therapeutics75.39%LCTXLineage Cell Therapeutics62.47%TRUUTrue DrinksN/AInsider OwnershipCompanyInsider OwnershipIMCRImmunocore10.40%JANXJanux Therapeutics29.40%LCTXLineage Cell Therapeutics26.80%TRUUTrue Drinks18.18%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableIMCRImmunocore32050.39 million45.15 millionOptionableJANXJanux Therapeutics3060.09 million42.43 millionOptionableLCTXLineage Cell Therapeutics60228.36 million167.16 millionNot OptionableTRUUTrue Drinks404.97 billionN/ANot OptionableLCTX, IMCR, JANX, and TRUU HeadlinesRecent News About These CompaniesBeer News: True Acts Of Aletruism / New “Indie Beer” CampaignNovember 13, 2024 | americancraftbeer.comAHow Much Alcohol Can You Drink a Week and Still Be Healthy?November 13, 2024 | msn.comStarbucks holiday menu: What's the healthiest drink? How much sugar, caffeine is in the seasonal beverages and other nutritional factsNovember 9, 2024 | msn.comCan You Drink Alcohol After Getting a COVID-19 Booster?October 29, 2024 | health.comHIt's True: Some Pizza Hut Locations Still Serve AlcoholOctober 22, 2024 | yahoo.comReview: True Story Finished BourbonOctober 21, 2024 | msn.comVitalizes Body and Mind.®October 4, 2024 | redbull.comR7UP confirms limited release of ‘most overdue’ soda flavor: ‘Dream come true’October 2, 2024 | msn.com‘Diabetes in a cup!’ Dunkin worker reveals most ‘absurd’ drink he’s ever made — here’s what’s in itSeptember 21, 2024 | nypost.comNSeattle’s True Loves Drop a Funky New SingleAugust 31, 2024 | msn.comCannabis Beverage of the Week: Nowadays stands out in a crowded field of THC drinksAugust 31, 2024 | msn.comThese alcoholic drinks can raise the risk of gout, a painful type of arthritisAugust 30, 2024 | nypost.comN14 Drinks You Should Think Twice About Ordering At A Bar, According To A Master MixologistAugust 29, 2024 | yahoo.com7 things you NEED to know about Prime Drinks (and the very different things the internet will tell you)August 25, 2024 | bbc.co.uk12 Unhealthiest Drinks You Should Think Twice About Ordering At A BarAugust 18, 2024 | msn.comTrue Loaf Bakery gets starter from two local bakersAugust 10, 2024 | msn.comPD TRUE : STREAM IT OR SKIP IT?August 6, 2024 | decider.comD10 Drinks People Fake Liking to Fit InAugust 5, 2024 | msn.com16 Best Summer Cocktails for a Hot Weather BuzzJuly 26, 2024 | esquire.comEWhat is ‘fluffy Coke’? Sugary drink dubbed ‘diabetes in a cup’ is the hottest beverage of the summerJuly 23, 2024 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeLCTX, IMCR, JANX, and TRUU Company DescriptionsImmunocore NASDAQ:IMCR$34.39 +2.67 (+8.42%) Closing price 04:00 PM EasternExtended Trading$34.35 -0.04 (-0.10%) As of 05:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.Janux Therapeutics NASDAQ:JANX$28.28 +2.55 (+9.91%) Closing price 04:00 PM EasternExtended Trading$28.26 -0.03 (-0.09%) As of 05:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.Lineage Cell Therapeutics NYSEAMERICAN:LCTX$1.81 +0.02 (+1.12%) Closing price 04:10 PM EasternExtended Trading$1.78 -0.03 (-1.38%) As of 05:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also offers ANP1, an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of debilitating hearing loss; and PNC1, an allogeneic photoreceptor cell transplant, which is in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage. In addition, the company engages in the research and development of therapeutic products for retinal diseases, neurological diseases, and disorders and oncology. Lineage Cell Therapeutics, Inc. has a collaboration with Immunomic Therapeutics, Inc., for the treatment of glioblastoma multiforme. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.True Drinks OTCMKTS:TRUU$0.29 -0.03 (-8.06%) As of 10/14/2025True Drinks Holdings, Inc. markets and distributes nutritional supplement drinks. The company sells Bazi All Natural Energy, a liquid nutritional supplement drink through drinkbazi.com. It also formulates products containing CBD; and produces and distributes vapor products in approximately 90 countries. The company was formerly known as True Drinks, Inc. and changed its name to True Drinks Holdings, Inc. in October 2012. True Drinks Holdings, Inc. was founded in 2008 and is headquartered in Irvine, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Walmart's AI Play: OpenAI Deal Forges a New Path to Profitability 3 Healthcare Companies Insiders Are Buying Tempus AI Hits $100—Are Shares Due for a Pullback? Vertiv Stock Surges on Strategic CFO Hire and AI Momentum NVIDIA Analysts Lift Targets: What It Means for the Stock Price Fastenal Stock Pulls Back in October—Is It Time to Buy FAST? 5 Stocks and ETFs to Weather Volatility as Trade Tensions Rise Why Congress Is Buying Intuitive Surgical Ahead of Earnings Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
